Pieris inks a li­cens­ing deal for Japan; Kindler joins Phar­ma Two B board with $30M raise; Am­pio plots new pain study

→ Boston-based Pieris $PIRS has op­tioned a li­cens­ing pact giv­ing AS­KA Phar­ma­ceu­ti­cal de­vel­op­ment and com­mer­cial­iza­tion rights for the ane­mia drug PRS-080 in Japan and cer­tain oth­er Asian mar­kets. Pieris gets a $2.75 mil­lion op­tion pay­ment on the deal, and if AS­KA agrees to for­mal­ly sign on af­ter look­ing over Phase IIa da­ta, then Pieris will be in line for up to $80 mil­lion in mile­stones. “We are pleased to have found a very com­mit­ted part­ner for PRS-080 in a key Asian mar­ket,” said Stephen Yo­der, the CEO of Pieris. “Im­por­tant­ly, this deal en­ables us to in­vest in im­prov­ing drug man­u­fac­tur­ing ef­fi­cien­cies while con­duct­ing our Phase 2a tri­al to en­able seam­less drug sup­ply for fu­ture clin­i­cal stud­ies by AS­KA and oth­er part­ners we may seek in oth­er ter­ri­to­ries, as we fo­cus our pro­pri­etary pipeline in im­munol­o­gy-re­lat­ed ar­eas for long-term val­ue cre­ation.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER